NASDAQ:HCWB HCW Biologics (HCWB) Stock Price, News & Analysis $1.98 -0.11 (-5.26%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$2.01 +0.03 (+1.67%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HCW Biologics Stock (NASDAQ:HCWB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HCW Biologics alerts:Sign Up Key Stats Today's Range$1.98▼$2.1750-Day Range$0.27▼$2.8952-Week Range$0.25▼$8.75Volume2.50 million shsAverage Volume36.34 million shsMarket Capitalization$13.33 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida. Read More HCW Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreHCWB MarketRank™: HCW Biologics scored higher than 62% of companies evaluated by MarketBeat, and ranked 377th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingHCW Biologics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialHCW Biologics has a consensus price target of $5.00, representing about 152.5% upside from its current price of $1.98.Amount of Analyst CoverageHCW Biologics has only been the subject of 2 research reports in the past 90 days.Read more about HCW Biologics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of HCW Biologics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HCW Biologics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHCW Biologics has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about HCW Biologics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted62.81% of the float of HCW Biologics has been sold short.Short Interest Ratio / Days to CoverHCW Biologics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HCW Biologics has recently increased by 573.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHCW Biologics does not currently pay a dividend.Dividend GrowthHCW Biologics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.79 News SentimentHCW Biologics has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for HCW Biologics this week, compared to 3 articles on an average week.Search Interest20 people have searched for HCWB on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows7 people have added HCW Biologics to their MarketBeat watchlist in the last 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of HCW Biologics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $270,961.00 in company stock, which represents 2.0334% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, HCW Biologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $270,961.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders9.10% of the stock of HCW Biologics is held by insiders.Percentage Held by Institutions2.96% of the stock of HCW Biologics is held by institutions.Read more about HCW Biologics' insider trading history. Receive HCWB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HCW Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HCWB Stock News HeadlinesHCW Biologics (NASDAQ:HCWB) CFO Rebecca Byam Purchases 14,235 SharesMay 28 at 7:16 AM | insidertrades.comHCW Biologics Inc. Regains Full Rights to HCW9206 and HCW9201, Positions for CAR-T Immunotherapy Market ExpansionMay 27 at 7:50 AM | quiverquant.comQThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman, and Nvidia CEO Jensen Huang may hold the answer to a $33 trillion problem - and analysts believe it could eventually be worth more than Apple, Microsoft, and Amazon combined. A former Pentagon and FBI consultant recently traveled to a secured site to investigate the companies behind this tech and identify the stocks involved.May 30 at 1:00 AM | Altimetry (Ad)HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from WugenMay 27 at 7:45 AM | globenewswire.comHCW Biologics Raises $4M in Private Placement FinancingMay 23, 2026 | theglobeandmail.comHCW Biologics (NASDAQ:HCWB) Raised to Hold at Wall Street ZenMay 23, 2026 | americanbankingnews.comE.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private PlacementMay 22, 2026 | globenewswire.comWhy Is HCW Biologics Stock Surging On Friday?May 22, 2026 | benzinga.comSee More Headlines HCWB Stock Analysis - Frequently Asked Questions How have HCWB shares performed this year? HCW Biologics' stock was trading at $0.9706 on January 1st, 2026. Since then, HCWB shares have increased by 104.0% and is now trading at $1.98. How were HCW Biologics' earnings last quarter? HCW Biologics Inc. (NASDAQ:HCWB) issued its quarterly earnings data on Thursday, May, 14th. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.81. The company had revenue of $6.54 million for the quarter, compared to analysts' expectations of $6.54 million. HCW Biologics had a negative net margin of 34.73% and a negative trailing twelve-month return on equity of 486.87%. When did HCW Biologics' stock split? HCW Biologics's stock reverse split on the morning of Friday, April 11th 2025.The 1-40 reverse split was announced on Tuesday, April 1st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did HCW Biologics IPO? HCW Biologics (HCWB) raised $45 million in an initial public offering (IPO) on Tuesday, July 20th 2021. The company issued 5,600,000 shares at a price of $8.00 per share. EF Hutton acted as the underwriter for the IPO and Revere Securities was co-manager. How do I buy shares of HCW Biologics? Shares of HCWB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HCW Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that HCW Biologics investors own include Jiuzi (JZXN), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Kiora Pharmaceuticals (KPRX), Rallybio (RLYB), Adial Pharmaceuticals (ADIL) and Aridis Pharmaceuticals (ARDS). Company Calendar Last Earnings5/14/2026Today5/30/2026Next Earnings (Estimated)8/07/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HCWB CIK1828673 Webwww.hcwbiologics.com Phone954-842-2024Fax954-842-2037Employees40Year Founded2018Price Target and Rating Average Price Target for HCW Biologics$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+152.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($9.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.96 million Net Margins-34.73% Pretax Margin-29.73% Return on Equity-486.87% Return on Assets-29.19% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.09 Sales & Book Value Annual Sales$50 thousand Price / Sales266.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book2.30Miscellaneous Outstanding Shares6,730,000Free Float6,121,000Market Cap$13.33 million OptionableNot Optionable Beta1.13 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:HCWB) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman, and Nvidia CEO Jensen Huang may hold the answer to ...Altimetry | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPre-IPO Warning: SPCX [Watch Now!]Tech investor James Altucher - who called Netflix, Facebook, and Bitcoin early - says the SpaceX IPO (Ticker: ...Paradigm Press | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HCW Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HCW Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
